COTI-2
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
COTI-2 activates mutant forms of p53.
p53 has varoius mechanisms of anticancer function and plays a critical role in genomic stability, apoptosis and inhibition of angiogenesis.
In vitro: Previous study tested the efficacy of COTI-2 against a diverse group of human cancer cell lines with different genetic mutation backgrounds. Results showed that COTI-2 efficiently inhibited the proliferation rate of all the tested cell lines following 72 h of treatment. Most cell lines showed nanomolar sensitivity to COTI-2 treatment. In addition, COTI-2 was significantly more effective at inhibiting tumor cell proliferation than either cetuximab or erlotinib in COLO-205, HCT-15, and SW620 cell lines. Notably, all three lines were insensitive to growth inhibition to any degree in response to low concentrations of cetuximab and erlotinib, but highly sensitive to even low doses of COTI-2 [1].
In vivo: The effects of COTI-2 on inhibiting the growth of HT-29 and SHP-77 xenografts in immunocompromised mice was assessed when intraperitoneally administered. It was found that COTI-2 at 10 mg/kg could significantly inhibit tumor growth in the HT-29 human colorectal tumor xenografts. In addition to reducing tumor volumes at specific times post-treatment, COTI-2 could also delay the time required for tumors to reach specified volumes [1].
Clinical trial: A study of COTI-2 for the treatment of advanced or recurrent gynecologic malignancies is currently recruiting patients [2].
References:
[1] Salim, K. Y.,Vareki, S.M.,Danter, W.R., et al. COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo. Oncotarget 7(27), (2016).
[2] https://clinicaltrials. gov/ct2/show/NCT02433626term=COTI-2&rank=1
Physical Appearance | A crystalline solid |
Storage | Store at -20°C |
M.Wt | 366.5 |
Cas No. | 1039455-84-9 |
Formula | C19H22N6S |
Solubility | ≤1mg/ml in DMSO;2.5mg/ml in dimethyl formamide |
Chemical Name | 4-(2-pyridinyl)-2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide-1-piperazinecarbothioic acid |
SDF | Download SDF |
Canonical SMILES | S=C(N/N=C1C(N=CC=C2)=C2CCC\1)N(CC3)CCN3C4=NC=CC=C4 |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
Quality Control & MSDS
- View current batch:
-
Purity ≥ 95.00% (E/Z mixture)
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)